An eight-miRNA signature as a potential biomarker for predicting survival in lung adenocarcinoma

BackgroundLung adenocarcinoma is a heterogernous disease that creates challenges for classification and management. The purpose of this study is to identify specific miRNA markers closely associated with the survival of LUAD patients from a large dataset of significantly altered miRNAs, and to assess the prognostic value of this miRNA expression profile for OS in patients with LUAD.MethodsWe obtained miRNA expression profiles and corresponding clinical information for 372 LUAD patients from The Cancer Genome Atlas (TCGA), and identified the most significantly altered miRNAs between tumor and normal samples. Using survival analysis and supervised principal components method, we identified an eight-miRNA signature for the prediction of overall survival (OS) of LUAD patients. The relationship between OS and the identified miRNA signature was self-validated in the TCGA cohort (randomly classified into two subgroups: n = 186 for the training set and n = 186 for the testing set). Survival receiver operating characteristic (ROC) analysis was used to assess the performance of survival prediction. The biological relevance of putative miRNA targets was also analyzed using bioinformatics.ResultsSixteen of the 111 most significantly altered miRNAs were associated with OS across different clinical subclasses of the TCGA-derived LUAD cohort. A linear prognostic model of eight miRNAs (miR-31, miR-196b, miR-766, miR-519a-1, miR-375, miR-187, miR-331 and miR-101-1) was constructed and weighted by the importance scores from the supervised principal component method to divide patients into high- and low-risk groups. Patients assigned to the high-risk group exhibited poor OS compared with patients in the low-risk group (hazard ratio [HR] = 1.99, P <0.001). The eight-miRNA signature is an independent prognostic marker of OS of LUAD patients and demonstrates good performance for predicting 5-year OS (Area Under the respective ROC Curves [AUC] = 0.626, P = 0.003), especially for non-smokers (AUC = 0.686, P = 0.023).ConclusionsWe identified an eight-miRNA signature that is prognostic of LUAD. The miRNA signature, if validated in other prospective studies, may have important implications in clinical practice, in particular identifying a subgroup of patients with LUAD who are at high risk of mortality.

[1]  Jeffrey W. Clark,et al.  Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Glickman,et al.  The Proteasome and the Delicate Balance between Destruction and Rescue , 2004, PLoS biology.

[3]  Ugo Pastorino,et al.  MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer , 2011, Proceedings of the National Academy of Sciences.

[4]  Akihiko Yoshizawa,et al.  Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases , 2011, Modern Pathology.

[5]  Sandrine Dudoit,et al.  Evaluation of statistical methods for normalization and differential expression in mRNA-Seq experiments , 2010, BMC Bioinformatics.

[6]  Peng-Fei Zhang,et al.  Identification of annexin A1 as a proinvasive and prognostic factor for lung adenocarcinoma , 2011, Clinical & Experimental Metastasis.

[7]  J. Jassem,et al.  Prognostic value of microRNA expression in operable non-small cell lung cancer patients , 2014, British Journal of Cancer.

[8]  K. Cummings,et al.  Smoking at diagnosis and survival in cancer patients , 2013, International journal of cancer.

[9]  J. Niland,et al.  Smoking status and survival in the national comprehensive cancer network non–small cell lung cancer cohort , 2013, Cancer.

[10]  C. Croce,et al.  MicroRNA-31 Predicts the Presence of Lymph Node Metastases and Survival in Patients with Lung Adenocarcinoma , 2013, Clinical Cancer Research.

[11]  J. Weinstein,et al.  Biomarkers in Cancer Staging, Prognosis and Treatment Selection , 2005, Nature Reviews Cancer.

[12]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[13]  Ming You,et al.  MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer. , 2012, Carcinogenesis.

[14]  Laoighse Mulrane,et al.  miR-187 Is an Independent Prognostic Factor in Breast Cancer and Confers Increased Invasive Potential In Vitro , 2012, Clinical Cancer Research.

[15]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[16]  M. Reiser,et al.  Micro-RNAs as Potential New Molecular Biomarkers in Oncology: Have They Reached Relevance for the Clinical Imaging Sciences? , 2013, Theranostics.

[17]  Lijing Wang,et al.  Cell-Specific Detection of miR-375 Downregulation for Predicting the Prognosis of Esophageal Squamous Cell Carcinoma by miRNA In Situ Hybridization , 2013, PloS one.

[18]  R. Tibshirani,et al.  Semi-Supervised Methods to Predict Patient Survival from Gene Expression Data , 2004, PLoS biology.

[19]  M. Robinson,et al.  A scaling normalization method for differential expression analysis of RNA-seq data , 2010, Genome Biology.

[20]  S. Jee,et al.  Impact of environmental tobacco smoke on the incidence of mutations in epidermal growth factor receptor gene in never-smoker patients with non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Xi Chen,et al.  Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  T. Betsuyaku,et al.  Identification of microRNAs differentially expressed between lung squamous cell carcinoma and lung adenocarcinoma. , 2013, Molecular medicine reports.

[23]  T. Lumley,et al.  Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker , 2000, Biometrics.

[24]  Lin Jiang,et al.  Decreased circulating miR-375: A potential biomarker for patients with non-small-cell lung cancer. , 2014, Gene.

[25]  A. Daley,et al.  Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis , 2010, BMJ : British Medical Journal.

[26]  B. Trink,et al.  Phospho-ΔNp63α is a key regulator of the cisplatin-induced microRNAome in cancer cells , 2011, Cell Death and Differentiation.

[27]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Yingyan Yu,et al.  miRNA-331-3p directly targets E2F1 and induces growth arrest in human gastric cancer. , 2010, Biochemical and biophysical research communications.

[29]  Norbert Gretz,et al.  miRWalk - Database: Prediction of possible miRNA binding sites by "walking" the genes of three genomes , 2011, J. Biomed. Informatics.

[30]  Yingdong Zhao,et al.  MicroRNA Expression Differentiates Histology and Predicts Survival of Lung Cancer , 2010, Clinical Cancer Research.

[31]  Sung-Liang Yu,et al.  MicroRNA signature predicts survival and relapse in lung cancer. , 2008, Cancer cell.

[32]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[33]  Duhee Bang,et al.  Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers , 2014, Genome Medicine.

[34]  F. Slack,et al.  MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy , 2011, Nature Reviews Cancer.

[35]  B. Johnson,et al.  The impact of genomic changes on treatment of lung cancer. , 2013, American journal of respiratory and critical care medicine.

[36]  L. Holmberg,et al.  Lung cancer incidence in never smokers. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Donglei Liu,et al.  MicroRNA-101 Exerts Tumor-Suppressive Functions in Non-small Cell Lung Cancer through Directly Targeting Enhancer of Zeste Homolog 2 , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[38]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[39]  T. Jiang,et al.  Upregulation of miR-196b Confers a Poor Prognosis in Glioblastoma Patients via Inducing a Proliferative Phenotype , 2012, PloS one.

[40]  Christina Backes,et al.  GeneTrail—advanced gene set enrichment analysis , 2007, Nucleic Acids Res..

[41]  E. Sontheimer,et al.  Origins and Mechanisms of miRNAs and siRNAs , 2009, Cell.

[42]  Lin He,et al.  MicroRNAs: small RNAs with a big role in gene regulation , 2004, Nature Reviews Genetics.

[43]  Fang Zhou,et al.  A 5-MicroRNA Signature for Lung Squamous Cell Carcinoma Diagnosis and hsa-miR-31 for Prognosis , 2011, Clinical Cancer Research.

[44]  S. Batra,et al.  Smoking and microRNA dysregulation: a cancerous combination. , 2014, Trends in molecular medicine.

[45]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[46]  Chaoqian Xu,et al.  MicroRNAs Contribute to Promyelocyte Apoptosis in As2O3-Treated APL Cells , 2013, Cellular Physiology and Biochemistry.

[47]  Yuchen Liu,et al.  MicroRNA-187, down-regulated in clear cell renal cell carcinoma and associated with lower survival, inhibits cell growth and migration though targeting B7-H3. , 2013, Biochemical and biophysical research communications.

[48]  Zhifu Sun,et al.  Increased miR-708 Expression in NSCLC and Its Association with Poor Survival in Lung Adenocarcinoma from Never Smokers , 2012, Clinical Cancer Research.

[49]  O. Kent,et al.  A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes , 2006, Oncogene.

[50]  S. Toyooka,et al.  Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.

[51]  Northern Europe,et al.  Age standardised incidence and mortality from cervical cancer worldwide per 100,000 women (GLOBOCAN 2012) , 2014 .

[52]  Yan-wen Yao,et al.  MiR-101 and Mcl-1 in non-small-cell lung cancer: expression profile and clinical significance , 2012, Medical Oncology.

[53]  V. Seshan,et al.  Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[54]  E. Dmitrovsky,et al.  MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. , 2010, The Journal of clinical investigation.

[55]  Jacques Ferlay,et al.  GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012 , 2013 .

[56]  S. Choi,et al.  Overexpression of miR-196b and HOXA10 characterize a poor-prognosis gastric cancer subtype. , 2013, World journal of gastroenterology.

[57]  L. van Neste,et al.  Genome-wide unmasking of epigenetically silenced genes in lung adenocarcinoma from smokers and never smokers. , 2014, Carcinogenesis.

[58]  N. Normanno,et al.  The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches , 2012, Expert opinion on therapeutic targets.